Trial of COVID-19 convalescent blood plasma finds no benefit in severely ill patients
Enrolment of critically ill patients into the convalescent plasma arm of the REMAP-CAP study has been temporarily halted, after an initial analysis of 912 patients showed a 2.2% probability it reduced death rates or decreased the number of days patients needed intensive care.
Source:
Reuters Health
SPS commentary:
This arm of the study has paused to enable completion of follow-up of all enrolled participants and a more complete analysis, including if any patient subgroups derived benefit. The trial will continue to recruit hospitalised COVID-19 patients who are moderately unwell and are not requiring intensive care, to assess if less severely ill patients benefit from the treatment.